<DOC>
	<DOCNO>NCT02301897</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy two oral dos Proellex administer 2 course treatment ( 18 week ) , separate Off-Drug Interval ( ODI ) , premenopausal woman symptomatic uterine fibroid .</brief_summary>
	<brief_title>A Multi-Center , Parallel Design , Randomized , Double-Blind Study Evaluate Safety Efficacy 6 12 mg ProellexÂ® ( Telapristone Acetate ) Administered Orally Treatment Premenopausal Women With Confirmed Symptomatic Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Is premenopausal female , 1847 Subject history least 3 regular menstrual cycle menorrhagia ( heavy bleeding ) due uterine fibroid Confirmed uterine fibroid ( ) screen Visit 1 historical pictorial blood loss assessment chart &gt; 120 mL blood loss , ensure subject menstrual blood loss least 80 mL Alkaline Hematin Assay ( baseline assessment period ) . A Body Mass Index ( BMI ) 18 45 inclusive Subject pregnant lactating attempt expect become pregnant entire study period Received investigational drug 30 day prior screen study Has intrauterine device place Observation history abnormal endometrial biopsy include presence endometrial intraepithelial neoplasia Subjects abnormally high liver enzymes liver disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>